CD274 and non-small cell lung carcinoma: To that end, cobolimab is currently being evaluated in combination with dostarlimab and docetaxel in COSTAR Lung (NCT04655976), an ongoing phase II/III study of patients with locally advanced or metastatic NSCLC treated with prior anti–PD-(L)1 and platinum-based doublet chemotherapies.